We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Collaboration to Develop Monoclonal Antibodies Targeting Cancer
News

Collaboration to Develop Monoclonal Antibodies Targeting Cancer

Collaboration to Develop Monoclonal Antibodies Targeting Cancer
News

Collaboration to Develop Monoclonal Antibodies Targeting Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Collaboration to Develop Monoclonal Antibodies Targeting Cancer "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MedImmune, Inc. and VasGene Therapeutics, Inc. have announced that they have entered into a collaborative agreement to develop cancer- focused monoclonal antibodies (MAbs) targeting a member of a subfamily of receptor tyrosine kinases, EphB4, as well as its ligand, EphrinB2.

Under the terms of the agreement, MedImmune will be responsible for the clinical development and commercialization of any resulting products.

VasGene will provide research and development support and receive an upfront fee, development and regulatory milestone payments, as well as royalties on any future marketed products.

"MedImmune continues to expand the breadth and depth of its oncology product pipeline with promising new antibodies, targets and technologies," said Peter A. Kiener, D.Phil., MedImmune's senior vice president, research.

"Adding antibodies against EphB4 and EphrinB2 to our portfolio builds upon our existing activities with Eph kinases, including ongoing work with EphA2 and EphA4.”

"As we further our research in this area, we hope to expand the growing body of knowledge regarding the role Eph receptors may play in cancers, and we look forward to working with VasGene to advance novel product candidates with potential therapeutic applications."

"We are extremely pleased to announce our collaboration with MedImmune," said Raymond A. Mirra, Jr., VasGene's chairman and chief executive officer.

"MedImmune is highly experienced in the successful development of antibodies, and together we are going to make every effort to advance these compounds into the clinic."

Advertisement